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Objectives This study sought to investigate safety and efﬁcacy of biolimus-eluting stents (BES) with
biodegradable polymer as compared with sirolimus-eluting stents (SES) with durable polymer
through 2 years of follow-up.
Background BES with a biodegradable polymer provide similar efﬁcacy and safety as SES with a dura-
ble polymer at 9 months. Clinical outcomes beyond the period of biodegradation of the polymer used
for drug release and after discontinuation of dual antiplatelet therapy are of particular interest.
Methods A total of 1,707 patients were randomized to unrestricted use of BES (n  857) or SES
(n  850) in an all-comers patient population.
Results At 2 years, BES remained noninferior compared with SES for the primary endpoint, which
was a composite of cardiac death, myocardial infarction, or clinically indicated target vessel revascu-
larization (BES 12.8% vs. SES 15.2%, hazard ratio [HR]: 0.84, 95% conﬁdence interval [CI]: 0.65 to 1.08,
pnoninferiority  0.0001, psuperiority  0.18). Rates of cardiac death (3.2% vs. 3.9%, HR: 0.81, 95% CI:
0.49 to 1.35, p  0.42), myocardial infarction (6.3% vs. 5.6%, HR: 1.12, 95% CI: 0.76 to 1.65, p 
0.56), and clinically indicated target vessel revascularization (7.5% vs. 8.6%, HR: 0.86, 95% CI: 0.62 to
1.20, p  0.38) were similar for BES and SES. The rate of deﬁnite stent thrombosis through 2 years
was 2.2% for BES and 2.5% for SES (p  0.73). For the period between 1 and 2 years, event rates for
deﬁnite stent thrombosis were 0.2% for BES and 0.5% for SES (p  0.42). After discontinuation of
dual antiplatelet therapy, no very late deﬁnite stent thrombosis occurred in the BES group.
Conclusions At 2 years of follow-up, the unrestricted use of BES with a biodegradable polymer
maintained a similar safety and efﬁcacy proﬁle as SES with a durable polymer. (Limus Eluted From a
Durable Versus Erodable Stent Coating [LEADERS]; NCT00389220) (J Am Coll Cardiol Intv 2011;4:
887–95) © 2011 by the American College of Cardiology Foundation
From the *Department of Cardiology, University Hospital Munich (Innenstadt), Munich, Germany; †Department of Cardiology,
Hospital Bogenhausen, Munich, Germany; ‡Herzzentrum Leipzig, Leipzig, Germany; §Thoraxcenter, Erasmus University,
Rotterdam, the Netherlands; Cardialysis, Rotterdam, the Netherlands; ¶Department of Cardiology, Bern University Hospital,
Bern, Switzerland; #Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; **Clinical Trials Unit Bern,
Bern University Hospital, Bern, Switzerland; ††Department of Cardiology, Triemli Spital, Zurich, Switzerland; ‡‡Department
sf
p
a
d
M
a
b
a
C
d
F
m
f
t
w
l
i
n
c
I
i
e
a
p
i
m
r
c
r
D
o
a
B
t
H
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 8 , 2 0 1 1
A U G U S T 2 0 1 1 : 8 8 7 – 9 5
Klauss et al.
2-Year Comparison of BES and SES
888Early generation drug-eluting stents (DES) releasing either
sirolimus or paclitaxel from durable polymer surface coatings
have been shown to reduce angiographic and clinical restenosis
compared with bare-metal stents (1–3). However, concerns
arose that early generation DES are associated with an in-
creased risk of very late (1 year) stent thrombosis (4,5).
Delayed healing and re-endothelialization as well as chronic
inflammation and hypersensitivity reactions have been identi-
fied as pathophysiological mechanisms leading to very late
stent thrombosis and may be related at least in part to the
permanent polymer coating (6,7). With the aim to further
improve the safety and efficacy of DES, a biolimus-eluting
stent (BES) has been designed with a biodegradable polymer
applied to the stent’s abluminal surface, which is metabolized
to water and carbon dioxide within 6 to 9 months. Biolimus is
a highly lipophilic sirolimus analog, which inhibits the mam-
malian target of rapamycin, and inhibits smooth muscle cell
proliferation by causing the arrest of the cell cycle at G0 with
imilar potency to sirolimus (8).
BES with biodegradable polymer coating have previously
been shown to be noninferior to a
SES with durable polymer in
terms of major adverse cardiovas-
cular events at 9-month follow-up
in the randomized LEADERS
(Limus Eluted From a Durable
Versus Erodable Stent Coating)
trial (9). Longer-term follow-up
beyond the period of biodegrada-
tion of the polymer used for drug
release and after discontinuation
of dual antiplatelet therapy is of
particular interest to determine
the late safety profile of this plat-
orm. We therefore investigated the clinical outcomes of
atients included into this study through 2 years with particular
ttention to the time period after discontinuation of mandatory
ual antiplatelet therapy.
ethods
Study population. The methods of the LEADERS trial
have been published previously (9). In brief, the study
applied an all-comers approach recruiting 1,707 patients
with chronic stable coronary artery disease or acute
of Cardiology, University Hospital, Zurich, Switzerland; §§Department of Cardiol-
ogy, Medical University of Silesia, Katowice, Poland;  Department of Cardiology,
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium; ¶¶Department of Cardiology,
Institut Cardiovasculaire Paris-Sud, Paris, France; and the ##Department of Cardi-
ology, Royal Brompton Hospital, London, United Kingdom. Dr. Linke has received
consulting fees from Medtronic. Dr. Eberli has received honoraria from Cordis and
Biosensors and research grants from Abbott, Biosensors, Boston Scientific, and
Terumo. Dr. Morice has been a board member or served on the Speakers’ Bureau for
Abbreviations
and Acronyms
BES  biolimus-eluting
stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)Boston Scientific, Cordis, Medtronic, and Biosensors. Dr. di Mario has received a
M
2coronary syndromes including ST-segment elevation
myocardial infarction, who were eligible for enrollment if
they had 1 lesion with diameter stenosis 50% and a
reference vessel diameter 2.25 to 3.5 mm. Selection
criteria were broad, reflecting routine clinical practice.
We set no limit for the number of treated lesions, vessels,
or lesion length, and excluded no patients on the basis of
comorbidity apart from the following pre-specified crite-
ria: known allergy to acetylsalicylic acid, clopidogrel,
heparin, stainless steel, sirolimus, biolimus, or contrast
material; planned surgery within 6 months of percutane-
ous coronary intervention (PCI) unless the dual anti-
platelet therapy could be maintained throughout the
perisurgical period; pregnancy; participation in another
trial before reaching the primary endpoint; and inability
to provide informed consent. The study complied with
the Declaration of Helsinki and was approved by all
institutional ethics committees. All patients provided
written, informed consent for participation in the trial.
Randomization and procedures. Patients were randomly
llocated on a 1:1 basis to treatment with a stent eluting
iolimus-A9 with a biodegradable polymer, polylactic
cid (BioMatrix Flex, Biosensors Inc., Newport Beach,
alifornia) or a sirolimus-eluting stent (SES) with a
urable polymer (Cypher Select, Cordis, Miami Lakes,
lorida) and to active angiographic follow-up at 9
onths or clinical follow-up only on a 1:3 basis using a
actorial design. BES were available in diameters of 2.25
o 3.5 mm and in lengths of 8 to 28 mm, whereas SES
ere available in diameters of 2.25 to 3.5 mm and in
engths of 8 to 33 mm. Balloon angioplasty and stent
mplantation were performed according to standard tech-
ique, and direct stenting was allowed. Procedural anti-
oagulation was achieved with unfractionated heparin 5,000
U or 70 to 100 IU/kg, whereas the use of glycoprotein IIb/IIIa
nhibitors was left to the operator’s discretion. All patients
nrolled into the study received 75 mg of acetylsalicylic acid
nd at least 300 mg of clopidogrel before the procedure. All
atients were discharged on 75 mg of acetylsalicylic acid
ndefinitely and clopidogrel 75 mg for a minimum of 12
onths following the index procedure. In the case of intercur-
ent revascularization procedures needing stent implantation,
ardiologists were encouraged to use study stents.
Follow-up. Adverse events were assessed in the hospital,
and clinical follow-up was performed at 1, 6, 9, 12, and
esearch grant from Biosensors. Dr. Wenaweser has received lecture fees from Cordis.
r. Jüni has been an unpaid member of steering groups and/or planning committees
f cardiovascular trials funded by Abbott Vascular, Biosensors, Cordis, Medtronic,
nd St. Jude Medical. Dr. Windecker has received research grants from Abbott,
oston Scientific, Biosensors, Cordis, and Medtronic. All other authors have reported
hat they have no relationships relevant to the contents of this paper to disclose. John
irshfeld, Jr., MD, served as Guest Editor for this paper.anuscript received November 22, 2010; revised manuscript received February 14,
011, accepted March 18, 2011.
s
i
l
h
i
i
f
a
s
c
s
T
s
p
b
w
(
u
e
m
(
(
E
p
e
i
i
(
a
a
m
w
p
0
2
i
C
c
W
9
g
v
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 8 , 2 0 1 1 Klauss et al.
A U G U S T 2 0 1 1 : 8 8 7 – 9 5 2-Year Comparison of BES and SES
88924 months. Additional clinical follow-up is planned at
yearly intervals to 5 years. One in 4 patients was asked to
return for angiographic follow-up at 9 months.
Study endpoints. The primary clinical endpoint of this
tudy was the composite of cardiac death, myocardial
nfarction, and clinically indicated target vessel revascu-
arization. The detailed definitions of these endpoints
ave been reported previously (9). Secondary endpoints
ncluded any target lesion revascularization (clinically
ndicated or nonclinically indicated); cardiac death; death
rom any cause; myocardial infarction; stent thrombosis
ccording to definitions of the Academic Research Con-
ortium (10). A blinded independent clinical events
ommittee adjudicated all endpoints, and independent
tudy monitors verified all case reports from data on site.
he operators were by necessity aware of the assigned
tudy stent during PCI and angiographic follow-up, but
atients and staff involved in follow-up assessment were
linded to the allocated stent type. Angiography films
ere centrally assessed at 1 angiographic core laboratory
Cardialysis, Rotterdam, the Netherlands) with assessors
naware of the allocated stent.
Statistics. This was a noninferiority trial, which was pow-
red for noninferiority on the primary clinical endpoint at 9
Figure 1. Flow Chart of Clinical Follow-Up of Patient Population
Patient ﬂow of the patients through the trial up to 2 years. BES  biolimus-elu
SES  sirolimus-eluting stent(s).onths. Based on event rates reported for the BASKET
Basel Stent Cost-Effectiveness Trial) (11) and SIRTAX
Sirolimus-Eluting Stent Compared With Paclitaxel-
luting Stent for Coronary Revascularization) (12) trials in
atients comparable to those to be included in this trial, we
xpected rates of the primary endpoint at 9 months to be 8%
n both treatment groups. Noninferiority would be declared
f the upper limit of the 1-sided 95% confidence interval
CI) of the absolute risk difference did not exceed 4%. Using
simulation-based approach with 10,000 simulations, with
continuity-corrected modification of the Wilson score
ethod to estimate confidence intervals for binary data (13),
e estimated that 850 patients per group yielded 90%
ower to detect noninferiority at a 1-sided type I error of
.05. After establishing noninferiority, we calculated regular
-sided 95% CI and 2-sided p values to allow conventional
nterpretation of results as if using a superiority design.
In the present analysis, the 2-year results are reported.
ontinuous variables are expressed as mean  SD; and
ategorical data are presented as frequency (percentages).
e used Mantel-Cox method to calculate rate ratios and
5% CI for comparisons of clinical outcomes between
roups, and the log-rank test to calculate corresponding p
alues. Survival curves were constructed for time-to-event
tent(s); PCI  percutaneous coronary intervention;ting s
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 8 , 2 0 1 1
A U G U S T 2 0 1 1 : 8 8 7 – 9 5
Klauss et al.
2-Year Comparison of BES and SES
890variables using Kaplan-Meier estimates. Stratified analy-
ses according to the presence or absence of diabetes, acute
coronary syndrome, acute ST-segment elevation myocar-
dial infarction, left anterior descending artery, multivessel
disease, off-label use, de-novo lesions, small-vessel dis-
ease, and long-lesions were carried out. To identify
possible interaction between treatment effect and these
characteristics, the chi-square test was used to test for
effect modification. A dedicated statistician performed all
analyses using SAS (version 8.02, SAS Institute Inc.,
Cary, North Carolina). All p values and CI were 2-sided
except for noninferiority of BES compared with SES for
Table 1. Baseline Clinical and Angiographic Characteristics
BES (n  857) SES (n  850)
Age, yrs 64.6 10.8 64.5 10.7
Male 643 (75.0%) 634 (74.6%)
Body mass index, kg/m2, mean 27.6 27.5
Diabetes mellitus 223 (26.0%) 191 (22.5%)
Hypertension 630 (73.5%) 618 (72.7%)
Hypercholesterolemia 560 (65.3%) 580 (68.2%)
Current smoker 206 (24.0%) 214 (25.2%)
Family history of CAD 339 (39.6%) 374 (44.0%)
Previous MI 276 (32.2%) 277 (32.6%)
Previous PCI 312 (36.4%) 312 (36.7%)
Previous CABG 90 (10.5%) 107 (12.6%)
Previous stroke 40 (4.7%) 28 (3.3%)
Peripheral vascular disease 70 (8.2%) 63 (7.4%)
Multivessel disease 209 (24.4%) 176 (20.7%)
Left ventricular ejection fraction, %* 55.9 11.3 55.4 12.4
SYNTAX score† 13.2 13.3
Acute coronary syndrome 470 (54.8%) 473 (55.7%)
ST-segment elevation MI 135 (15.8%) 140 (16.5%)
Non–ST-segment elevation MI 145 (16.9%) 153 (18.0%)
Unstable angina 190 (22.2%) 180 (21.2%)
Stable angina 387 (45.2%) 377 (44.4%)
Silent ischemia 89 (10.4%) 85 (10.0%)
De-novo lesions 1,181/1,256 (94.0%) 1,126/1,213 (92.9%)
Off-label use 696 (81.2%) 665 (78.2%)
Small-vessel disease, RVD 2.75 mm 585 (68.3%) 568 (66.8%)
Lesions 20 mm 262 (30.6%) 225 (26.5%)
RVD, mm‡ 2.60 0.61 2.60 0.57
Minimum lumen diameter, mm§ 0.91 0.50 0.95 0.52
Diameter stenosis, %§ 64.6 17.9 63.3 18.2
Values are mean SD or n (%). *Left ventricular ejection fraction is available for 601 BES and 607
SES patients. †SYNTAX score is for 678 patients in the BES group and 673 in the SES group. ‡RVD
was assessed for 1,246 patients in the BES group and 1,199 in the SES group. §Minimum lumen
diameter was assessed for 1,209 patients in the BES group and 1,186 in the SES group.
BES  biolimus-eluting stent(s); CABG  coronary artery bypass grafting; CAD  coronary
artery disease; MI  myocardial infarction; PCI  percutaneous coronary intervention; RVD 
reference vessel diameter; SES sirolimus-eluting stent(s); SYNTAX Synergy Between Percu-
taneous Coronary Intervention With Taxus and Cardiac Surgery trial.the primary endpoint.Results
Figure 1 shows the flow of patients from enrollment to 2 years
on an intention-to-treat basis. Overall, clinical follow-up was
available in 1,670 patients (97.5%): 836 of 857 BES patients
(97.1%), and 834 of 850 SES patients (98.1%). The baseline
clinical and angiographic characteristics were similar in both
groups (Table 1). There was no significant difference in
procedural characteristics between both groups.
Clinical outcomes at 2 years. Table 2 shows clinical out-
comes at 2 years. The primary endpoint occurred in 110
(12.8%) BES patients and 129 (15.2%) SES patients (Fig. 2).
Noninferiority of BES compared with SES was maintained
at 2 years with an absolute risk difference of 2.4%, the
boundary of the 1-sided 95% CI at 0.5%, and the corre-
sponding 1-sided p value for noninferiority at 0.0001.
Superiority testing of the primary endpoint yielded nonsig-
nificant differences between BES and SES (p  0.18)
(Table 2). The use of BES compared with SES was
associated with similar rates of cardiac death (3.2% vs. 3.9%;
hazard ratio [HR]: 0.81; 95% CI: 0.49 to 1.35; p  0.42)
and myocardial infarction (6.3% vs. 5.6%; HR: 1.12; 95%
Table 2. Clinical Outcomes at 2 Years
Event
BES
(n  857)
SES
(n  850) HR (95% CI) p Value
Death 40 (4.7) 43 (5.1) 0.92 (0.60–1.42) 0.71
Cardiac death 27 (3.2) 33 (3.9) 0.81 (0.49–1.35) 0.42
Myocardial infarction 54 (6.3) 48 (5.6) 1.12 (0.76–1.65) 0.56
Q-wave 4 (0.5) 8 (0.9) 0.49 (0.15–1.64) 0.25
Non–Q-wave 50 (5.8) 41 (4.8) 1.22 (0.81–1.84) 0.35
Clinically indicated TLR 55 (6.4) 60 (7.1) 0.90 (0.63–1.30) 0.59
Percutaneous 50 (5.8) 55 (6.5) 0.90 (0.61–1.32) 0.58
Surgical 8 (0.9) 9 (1.1) 0.88 (0.34–2.28) 0.79
Any TLR 68 (7.9) 74 (8.7) 0.91 (0.65–1.26) 0.55
Percutaneous 61 (7.1) 67 (7.9) 0.90 (0.64–1.27) 0.55
Surgical 11 (1.3) 13 (1.5) 0.84 (0.38–1.87) 0.67
Clinically indicated TVR 64 (7.5) 73 (8.6) 0.86 (0.62–1.20) 0.38
Percutaneous 58 (6.8) 66 (7.8) 0.86 (0.61–1.23) 0.42
Surgical 10 (1.2) 12 (1.4) 0.83 (0.36–1.91) 0.65
Any TVR 83 (9.7) 96 (11.3) 0.85 (0.63–1.13) 0.26
Percutaneous 73 (8.5) 83 (9.8) 0.86 (0.63–1.18) 0.36
Surgical 15 (1.8) 19 (2.2) 0.78 (0.40–1.53) 0.47
Any repeat revascularization 83 (9.7) 99 (11.6) 0.82 (0.61–1.10) 0.18
Percutaneous 73 (8.5) 83 (9.8) 0.86 (0.63–1.18) 0.36
Surgical 15 (1.8) 22 (2.6) 0.67 (0.35–1.30) 0.24
Death or MI 82 (9.6) 85 (10.0) 0.96 (0.71–1.30) 0.79
Cardiac death or MI 70 (8.2) 76 (8.9) 0.92 (0.66–1.27) 0.60
Cardiac death, MI, or clinically
indicated TLR
102 (11.9) 116 (13.6) 0.87 (0.67–1.13) 0.30
Cardiac death, MI, or clinically
indicated TVR
110 (12.8) 129 (15.2) 0.84 (0.65–1.08) 0.18
Values are n (%).
CI confidence interval; HR hazard ratio; TLR target lesion revascularization; TVR targetvessel revascularization; other abbreviations as in Table 1.
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891CI: 0.76 to 1.65; p  0.60). In addition, clinically indicated
target vessel revascularization was comparable between BES
and SES patients (7.5% vs. 8.6%; HR: 0.86; 95% CI: 0.62
to 1.20; p  0.38) (Fig. 2).
The findings for the primary endpoint were consistent
across the pre-specified stratified analyses for diabetes, acute
coronary syndromes, and de novo lesions, as well as other
subgroups including lesion in the left anterior descending
artery, small-vessel disease, long lesions, and off-label use
(Fig. 3). A significant interaction was observed between
estimated HR and presence or absence of ST-segment
elevation myocardial infarction at baseline (p for interac-
A
C
Figure 2. Clinical Outcome Up to 2 Years of Follow-Up
(A) Time-to-event curves are shown for the primary endpoint of cardiac de
tion up to 2 years of follow-up for the BES (blue) and the SES (orange). Th
to-event curves are shown for the endpoint of clinically indicated target ve
(orange). The p values are 2-sided from superiority testing using a log-ran
myocardial infarction up to 2 years of follow-up for the BES (blue) and the
rank test. HR  hazard ratio; MACE  major adverse cardiac event(s); MI 
tions as in Figure 1.tion  0.02). A lower rate of major adverse cardiovascularvents in BES compared with SES was apparent in
atients with ST-segment elevation myocardial infarc-
ion (HR: 0.40, 95% CI: 0.20 to 0.80), but not in
emaining patients (HR: 0.96, 95% CI: 0.73 to 1.27).
Stent thrombosis and antiplatelet therapy. The rates of
stent thrombosis as per the Academic Research Consor-
tium’s definitions are listed in Table 3. There was no
significant difference in definite, probable, or possible stent
thrombosis during the early, late, or very late stent time
period between both groups. There was 1 secondary
definite late stent thrombosis in a SES patient at 60 days
who experienced an early stent thrombosis at 3 days.
yocardial infarction, and clinically indicated target vessel revasculariza-
alues are 2-sided from superiority testing using a log-rank test. (B) Time-
evascularization up to 2 years of follow-up for the BES (blue) and the SES
. (C) Time-to-event curves are shown for the endpoint of cardiac death or
orange). The p values are 2-sided from superiority testing using a log-
cardial infarction; TVR  target vessel revascularization; other abbrevia-B
ath, m
e p v
ssel r
k test
SES (
myoDefinite very late stent thrombosis occurred among 0.2%
other abbreviations as in Figure 1.
ARC Academic Research Consortium; other abbreviations as in Table 1.
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892of patients treated with BES and 0.5% of patients treated
with SES (Fig. 4) between 1 and 2 years of follow-up.
Table 4 summarizes the timing, lesion characteristics,
clinical indication at baseline, clinical consequence, and
relationship to dual antiplatelet therapy of very late
definite stent thrombosis.
As shown in Table 5, aspirin use was high throughout the
2-year period. Per protocol, thienopyridine use was recom-
mended for 12 months, but its use declined to 68.1% in the
BES group and 66.5% in the SES group at 12 months and
to 23.4% and 24.3% at 24 months, respectively. In 317
patients who discontinued dual antiplatelet therapy before
12 months, no definite stent thrombosis was observed in the
BES group (0 of 154) compared with 1.2% in the SES
group (2 of 163). Among the 963 patients who discontinued
thienopyridine therapy after 12 months, very late stent
thrombosis rate amounted to 0% in BES patients (0 of 484)
and 0.6% in SES patients (3 of 479).
Discussion
This randomized study confirmed the efficacy and safety of
endpoint at 2 years among subgroups of patients randomly assigned to BES
he variable and the relative treatment effect. MI  myocardial infarction;Figure 3. Stratified Analysis of the Primary Endpoint
Data are shown with relative risks and 95% conﬁdence intervals (CI) for the primary
or SES. The p value for interaction represents the likelihood of interaction between tTable 3. Stent Thrombosis According to ARC Definitions
BES (n  857) SES (n  850) p Value
Deﬁnite stent thrombosis
Early 14 (1.6%) 14 (1.6%) 0.99
Late 3 (0.4%) 4 (0.5%) 0.70
Very late 2 (0.2%) 4 (0.5%) 0.42
Overall 19 (2.2%) 21 (2.5%)* 0.73
Probable stent thrombosis
Early 5 (0.6%) 2 (0.2%) 0.28
Late 2 (0.2%) 0 (0.0%) 1.00
Very late 0 (0.0%) 0 (0.0%) —
Overall 7 (0.8%) 2 (0.2%) 0.12
Possible stent thrombosis
Early 0 (0.0%) 0 (0.0%) —
Late 7 (0.8%) 9 (1.1%) 0.60
Very late 7 (0.8%) 8 (0.9%) 0.78
Overall 14 (1.6%) 17 (2.0%) 0.57
Deﬁnite or probable stent thrombosis
Early 18 (2.1%) 16 (1.9%) 0.74
Late 5 (0.6%) 4 (0.5%) 0.75
Very late 2 (0.2%) 4 (0.5%) 0.42
Overall 25 (2.9%) 23 (2.7%)* 0.79
Values are n (%). The timeperiods are: early 0–30days; late 31–360days; very late 361–720
days; overall 0–720 days. *Excludes 1 definite secondary stent thrombosis, which occurred in a
patient at 60 days, who had already experienced a stent thrombosis at 3 days.BES with an abluminal biodegradable polymer compared
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893with SES with a durable polymer at 2 years of follow-up.
The primary endpoint—a composite of cardiac death, myo-
cardial infarction, and clinically indicated target vessel
revascularization—demonstrated noninferiority of BES to
SES. Stent thrombosis continued to occur between 1 and 2
years in the BES group, but the overall incidence was low in
this all-comer patient population, and there was no apparent
relationship with the discontinuation of dual antiplatelet
therapy.
Whereas most previous DES trials recruited patients with
on-label characteristics, more than one-half of patients under-
going PCI with DES in routine clinical practice have at least 1
off-label characteristic (14). Of note, compared with standard
use, early and late DES safety is inferior in patients with
off-label characteristics, and the long-term effectiveness of
DES is also inferior with both off-label and untested use
(14,15). Consequently, the Circulatory System Devices Advi-
sory Panel of the U.S. Food and Drug Administration under-
lined the need for conducting studies in off-label indications
(16). The current study followed this recommendation and
enrolled patients undergoing PCI with the unrestricted use of
Figure 4. Definite Stent Thrombosis
Time-to-event curves for the endpoint of deﬁnite stent thrombosis up to 2
years of follow-up for the BES (blue) and the SES (orange). The p values
are 2-sided from superiority testing using a log-rank test. HR  hazard
ratio; other abbreviations as in Figure 1.
Table 4. Characteristics of Very Late Definite ST
Day Patient ID Stent Type Lesion Type D
446 006–132 SES De novo
515 001–190 BES SVG
536 002–288 SES De novo
593 008–055 SES SVG
672 007–049 BES SVG
714 006–36 SES De novoDAPT dual antiplatelet therapy; ST stent thrombosis; STEMI ST-segment elevation myocardial infarcDES to reflect routine clinical practice. Most patients had an
acute coronary syndrome and more than three-quarters of
patients received 1 or more DES for an off-label indication.
This may have contributed to the fact that the 2-year event
rates reported in this study were somewhat higher than those
observed in recent DES trials with lower risk profiles but
comparable during the follow-up period (17,18). A recent
study compared a second-generation everolimus-eluting stent
with a first-generation paclitaxel-eluting stent in a similar
patient population (COMPARE [Comparison of the
Everolimus-Eluting Xience-V Stent With the Paclitaxel-
Eluting Taxus Liberte Stent in All-Comers: A Randomized
Open Label Trial]) (19). Overall, the everolimus-eluting stent
was superior to the paclitaxel-eluting stent, and event rates at 1
year were lower for both stents than in the current trial. As
COMPARE used a different comparator, it remains to be
determined whether a comparison with sirolimus-eluting
stents would have altered the results.
The use of early generation DES has been associated with
increased rates of very late (beyond 1 year) stent thrombosis
compared with bare-metal stents, a difference that emerged
particularly in off-label indications (14,15,20,21). Although the
occurrence of very late stent thrombosis remains largely unpre-
dictable and no specific cause has been identified, the proper-
ties of the polymer used for controlled drug release may be
related to the pathophysiological mechanisms leading to this
adverse event. Histopathological studies have shown that DES
with durable polymers can induce inflammation, eosinophilic
Clinical Presentation at Baseline Clinical Presentation of ST
Non-STEMI Non-STEMI
STEMI Non-STEMI
Stable angina II Unstable angina
Stable angina II Non-STEMI
Unstable angina IIb Non-STEMI
Stable angina III Unstable angina
Table 5. Antiplatelet Agent Use
BES SES p Value
Aspirin
6 months 96.6% 97.4% 0.39
12 months 97.0% 96.1% 0.34
24 months 94.9% 94.2% 0.58
Clopidogrel/thienopyridine
6 months 95.6% 95.2% 0.81
12 months 68.1% 66.5% 0.52
24 months 23.4% 24.3% 0.72
Values are percentage of n.
Abbreviations as in Table 1.APT
Yes
Yes
No
No
Yes
Notion; SVG saphenous vein graft; other abbreviations as in Table 1.
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894infiltrates, and vessel remodeling, which may allow for fibrin
and platelet deposition and, in conjunction with altered flow
dynamics, promote local thrombosis (22,23). The BES used in
this study has a biodegradable polymer, located only on the
abluminal surface of the stent. This polymer is coreleased with
biolimus during a period of 6 to 9 months and degrades into
carbon dioxide and water (8). After 1 year, definite stent
hrombosis continued to occur with both BES (0.2%) and SES
0.5%, p  0.42). The rate of very late definite stent throm-
osis of 0.5% encountered with SES is reminiscent of the
nnual rate of 0.53% (95% CI: 0.44% to 0.64%) previously
eported with early generation DES (24). The small and
onsignificant difference in the rates of very late definite stent
hrombosis observed in the current study, however, can neither
rove nor disprove the concept of a biodegradable polymer
sed for drug release. Longer-term follow-up and studies of
arger patient populations are required to assess whether a
iodegradable polymer will meaningfully influence the occur-
ence of very late stent thrombosis. The optimal duration of
ual antiplatelet therapy after implantation of DES is not clear,
nd the risk of bleeding has to be balanced against the potential
enefit of secondary prevention and the risk of stent throm-
osis (25,26). In the present study, discontinuation of dual
ntiplatelet therapy before 12 months (per protocol, clopi-
ogrel was recommended for at least 12 months) was associ-
ted with a rate of stent thrombosis in the SES group of 1.2%,
hereas no event was observed in the BES group. When dual
ntiplatelet therapy was discontinued after 12 months, the
ate of stent thrombosis was 0.6% in the SES group
ompared with 0% in the BES group. Whether these
esults in the BES group are due to the properties of the
iodegradable polymer or just incidental remains specu-
ative at this point. However, results from a substudy
sing optical coherence tomography imaging at 9 months
evealed more complete strut coverage with BES than
ith SES, suggesting a difference in healing properties
nd therefore the potential substrate for stent thrombosis.
onclusions
At 2 years of follow-up, the unrestricted use of BES with a
biodegradable polymer maintained a similar safety and
efficacy profile as SES with a durable polymer.
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